RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase

Obr AE, Edwards DP (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357:4–17 Schramek D, Sigl V, Penninger JM (2011) RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 22:188–194 Fernandez-Valdivia R, Lydon JP (2012) From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol 357:91–100 Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Schneider P et al (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107:2989–2994 Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R et al (2010) RANK ligand mediates progestin induced mammary epithelial proliferation and carcinogenesis. Nature 468:103–107 Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98–102 Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL et al (2010) Progesterone induces adult mammary stem cell expansion. Nature 465:803–807 Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER et al (2010) Control of mammary stem cell function by steroid hormone signaling. Nature 465:798–802 Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548–553 Beral V (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362:419–427 Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M (2006) Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer 118:1285–1291 Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692 Ferguson DJ, Anderson TJ (1981) Morphological evaluation of cell turnover in relation to the menstrual cycle in the ‘resting’ human breast. Br J Cancer 44:177–181 Ferguson DJ (1988) An ultrastructural study of mitosis and cytokinesis in normal ‘resting’ human breast. Cell Tissue Res 252:581–587 Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ (1989) Oral contraceptive use influences resting breast proliferation. Hum Pathol 20:1139–1144 Anderson TJ, Ferguson DJ, Raab GM (1982) Cell turnover in the ‘resting’ human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 46:376–382 Going JJ, Anderson TJ, Battersby S, MacIntyre CC (1988) Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130:193–204 Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M et al (1988) The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58:163–170 Bai M, Agnatis NJ, Kamina S, Demou A, Zagorianakou P, Katsaraki A et al (2001) In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res 3:276–283 Feuerhake F, Sigg W, Höfter EA, Unterberger P, Welsch U (2003) Cell proliferation, apoptosis, and expression of Bcl-2 and Bax in non-lactating human breast epithelium in relation to the menstrual cycle and reproductive history. Breast Cancer Res Treat 77:37–48 Capuco AV, Ellis S, Wood DL, Akers RM, Garrett W (2002) Postnatal mammary ductal growth: three-dimensional imaging of cell proliferation, effects of estrogen treatment, and expression of steroid receptors in prepubertal calves. Tissue Cell 34:143–154 Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987–4991 Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217–227 Seagroves TN, Lydon JP, Hovey RC, Vonderhaar BK, Rosen JM (2000) C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. Mol Endocrinol 14:359–368 Rajaram RD, Brisken C (2012) Paracrine signaling by progesterone. Mol Cell Endocrinol 357:80–90 Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI et al (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150:3318–3326 Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF et al (2013) Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5(182):182ra55 Ramakrishnan R, Khan SA, Badve S (2002) Morphological changes in breast tissue with menstrual cycle. Mod Pathol 15:1348–1356 Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37–42 Lee O, Helenowski IB, Chatterton RT, Jovanovic B, Khan SA (2012) Prediction of menopausal status from estrogen-related gene expression in benign breast tissue. Breast Cancer Res Treat 131:1067–1076 Wang J, Gupta A, Hu H, Chatterton RT, Clevenger CV, Khan SA (2013) Comment on “Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5(215):215le4 Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H et al (2013) Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer. Cancer Prev Res 6:321–330 Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S et al (2000) Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92:1217–1227 Chatterton RT, Khan SA, Heinz R, Ivancic D, Lee O (2010) Patterns of sex steroid hormones in nipple aspirate fluid during the menstrual cycle and after menopause in relation to serum concentrations. Cancer Epidemiol Biomark Prev 19:275–279 Burger HG, Dudley EC, Robertson DM, Dennerstein L (2002) Hormonal changes in the menopause transition. Recent Prog Horm Res 57:257–275 Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, Stricker R (2006) Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med 44:883–887 Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K et al (2013) Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res 15:R62 Brisken C (2013) Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 13:385–396 Jankowitz RC, McGuire KP, Davidson NE (2013) Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. Breast 22:S165–S170 Casula S, Bianco AC (2012) Thyroid hormone deiodinases and cancer. Front Endocrinol 3:74 Debski MG, Pachucki J, Ambroziak M, Olszewski W, Bar-Andziak E (2007) Human breast cancer tissue expresses high level of type 1 5-deiodinase. Thyroid 17:3–10 Dentice M, Luongo C, Huang S, Ambrosio R, Elefante A, Mirebeau-Prunier D et al (2007) Sonic hedgehog-induced type3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc Natl Acad Sci USA 104:14466–14471 Chen Z, Zhao TJ, Li J, Gao YS, Meng FG, Yan YB et al (2011) Slow skeletal muscle myosin-binding protein-C (MyBPC1) mediates recruitment of muscle-type creatine kinase (CK) to myosin. Biochem J 436:437–445